Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition.
Commun Biol
; 3(1): 782, 2020 12 17.
Article
em En
| MEDLINE
| ID: mdl-33335291
ABSTRACT
Protease-activated receptor-2 (PAR2) has been implicated in multiple pathophysiologies but drug discovery is challenging due to low small molecule tractability and a complex activation mechanism. Here we report the pharmacological profiling of a potent new agonist, suggested by molecular modelling to bind in the putative orthosteric site, and two novel PAR2 antagonists with distinctly different mechanisms of inhibition. We identify coupling between different PAR2 binding sites. One antagonist is a competitive inhibitor that binds to the orthosteric site, while a second antagonist is a negative allosteric modulator that binds at a remote site. The allosteric modulator shows probe dependence, more effectively inhibiting peptide than protease activation of PAR2 signalling. Importantly, both antagonists are active in vivo, inhibiting PAR2 agonist-induced acute paw inflammation in rats and preventing activation of mast cells and neutrophils. These results highlight two distinct mechanisms of inhibition that potentially could be targeted for future development of drugs that modulate PAR2.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Receptor PAR-2
/
Regulação Alostérica
/
Sítio Alostérico
/
Ligantes
Idioma:
En
Revista:
Commun Biol
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Suécia